These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35204396)

  • 21. Negative spinal bone mineral density changes and subclinical ovulatory disturbances--prospective data in healthy premenopausal women with regular menstrual cycles.
    Li D; Hitchcock CL; Barr SI; Yu T; Prior JC
    Epidemiol Rev; 2014; 36():137-47. PubMed ID: 24275546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Menstrual cycle lengths and bone mineral density: a cross-sectional, population-based study in rural Chinese women ages 30-49 years.
    Ouyang F; Wang X; Arguelles L; Rosul LL; Venners SA; Chen C; Hsu YH; Terwedow H; Wu D; Tang G; Yang J; Xing H; Zang T; Wang B; Xu X
    Osteoporos Int; 2007 Feb; 18(2):221-33. PubMed ID: 17019519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of follicle-stimulating hormone correlate with alkaline phosphatase and a marker for vitamin K status in the perimenopause.
    Lukacs JL; Reame NE
    J Womens Health Gend Based Med; 2000 Sep; 9(7):731-9. PubMed ID: 11025865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone predictors of bone mineral density changes during the menopausal transition.
    Sowers MR; Jannausch M; McConnell D; Little R; Greendale GA; Finkelstein JS; Neer RM; Johnston J; Ettinger B
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1261-7. PubMed ID: 16403818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
    Khan A; Dubois S; Khan AA; Zohair Rahman M; Ahmed Khan O; Syed HT; Derzko C
    J Obstet Gynaecol Can; 2014 Nov; 36(11):976-982. PubMed ID: 25574674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss.
    Gutierrez-Buey G; Restituto P; Botella S; Monreal I; Colina I; Rodríguez-Fraile M; Calleja A; Varo N
    Clin Endocrinol (Oxf); 2019 Sep; 91(3):391-399. PubMed ID: 31141196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners.
    De Souza MJ; Miller BE; Sequenzia LC; Luciano AA; Ulreich S; Stier S; Prestwood K; Lasley BL
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2867-76. PubMed ID: 9284712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lumbar and femoral bone density in perimenopausal women with irregular cycles.
    Perrone G; Galoppi P; Capri O; Anelli G; Borrello M; Zichella L
    Int J Fertil Menopausal Stud; 1995; 40(3):120-5. PubMed ID: 7663538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors predicting bone mineral density (BMD) changes in young women over a one-year study:changes in body weight and bone metabolic markers during the menstrual cycle and their effects on BMD.
    Iida T; Chikamura C; Ishikawa H; Aoi S; Ikeda H; Harada T; Katada K; Ishizaki F; Yatsuya H; Ono Y
    Acta Med Okayama; 2012; 66(4):307-15. PubMed ID: 22918203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density.
    Rannevik G; Jeppsson S; Johnell O; Bjerre B; Laurell-Borulf Y; Svanberg L
    Maturitas; 2008; 61(1-2):67-77. PubMed ID: 19434880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure.
    Mumford SL; Steiner AZ; Pollack AZ; Perkins NJ; Filiberto AC; Albert PS; Mattison DR; Wactawski-Wende J; Schisterman EF
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E1871-9. PubMed ID: 22837188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of bone mineral density (BMD) with quantitative computed tomography (QCT) in postmenopausal osteoporosis: effect of estrogen.
    Zgliczyński S; Szulc P; Słowińska-Srzednicka J; Stopińska-Głuszak U; Misiorowski W; Jeske W; Snochowska H; Wagiel K; Walecki J
    Endokrynol Pol; 1992; 43(3):350-7. PubMed ID: 1345576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women.
    Caird LE; Reid-Thomas V; Hannan WJ; Gow S; Glasier AF
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):739-45. PubMed ID: 7889609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women.
    Chapurlat RD; Garnero P; Sornay-Rendu E; Arlot ME; Claustrat B; Delmas PD
    Osteoporos Int; 2000; 11(6):493-8. PubMed ID: 10982164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical training and hormone replacement therapy reduce the decrease in bone mineral density in perimenopausal women: a pilot study.
    Bergström I; Freyschuss B; Landgren BM
    Osteoporos Int; 2005 Jul; 16(7):823-8. PubMed ID: 15536539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional bone mineral density differences measured by quantitative computed tomography: does the standard clinically used L1-L2 average correlate with the entire lumbosacral spine?
    Salzmann SN; Shirahata T; Yang J; Miller CO; Carlson BB; Rentenberger C; Carrino JA; Shue J; Sama AA; Cammisa FP; Girardi FP; Hughes AP
    Spine J; 2019 Apr; 19(4):695-702. PubMed ID: 30343044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma gonadotropins and ovarian hormones during the estrous cycle in high compared to low ovulation rate gilts.
    Knox RV; Vatzias G; Naber CH; Zimmerman DR
    J Anim Sci; 2003 Jan; 81(1):249-60. PubMed ID: 12597396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.